Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients
The DOI matches its Crossref record.
Abstract
Purpose: Serotonin (5-hydroxytryptamine type 3 [5-HT 3]) receptor antagonists have substantially reduced but not eliminated nausea and vomiting in patients undergoing cancer chemotherapy. They act through specific binding to the 5-HT 3A, 5-HT 3B receptor complex. The 5-HT 3B subunit seems to be most important for its functionality. We hypothesized that patients with genetic variations in the 5-HT 3B receptor gene might respond differently to antiemetic treatment. Patients and Methods: We included 242 cancer patients on their first day of chemotherapy. Nausea and vomiting were documented before and twice during the chemotherapy using standardized interviews and visual analog scales. We sequenced the entire 5-HT 3B receptor gene, including the 5` flanking region and at least a 20–base pair intronic sequence of each intron-exon splice site of all patients. Results: Approximately 30% of all patients suffered from nausea or vomiting. Sequencing of the 5-HT 3B receptor gene revealed 13 polymorphisms: two of them were amino acid exchanges (Tyr129Ser, Ala223Thr) and two were deletion variants. In both observation periods, patients homozygous for the −100_−102delAAG deletion variant of the promotor region experienced vomiting more frequently than did all the other patients. Conclusion: A more efficient antiemetic treatment with 5-HT 3 receptor antagonists might be possible on a pharmacogenetic basis. However, only a small fraction of the therapeutic failure is explained by the −AAG deletion variant of the 5-HT 3B receptor gene. Additional clinical and biochemical studies are needed to confirm the association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
The 5-HT3 receptor – the relationship between structure and function
Barnes, N. M., Hales, T. G., Lummis, S. C. R., & Peters, J. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.003 · Cited by 258
The 5-HT3receptor as a therapeutic target
Thompson, A. J., & Lummis, S. C. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.527 · Cited by 257
Treatment of nausea and vomiting: Gaps in our knowledge
Sanger, G. J., & Andrews, P. L. R. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.009 · Cited by 209
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113
Serotonin Type 3 Receptor Genes: HTR3A, B, C, D, E
Niesler, B., Kapeller, J., Hammer, C., & Rappold, G. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.501 · Cited by 78
Pharmacogenetics‐Based New Therapeutic Concepts
Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., et al. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033458 · Cited by 33
“When searching for a possible pharmacogenetic clue to the mechanism of therapeutic failure, Tremblay et al. (2003) found out that the AAG deletion in the promoter region of the 5-HT3-receptor ( 100_ 102 nucleotide position) was significantly more frequent in patients with T a b le 3 .”
BackgroundSelf-citationJanicki, P. K., & Sugino, S. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3968-z · Cited by 30
Joy Lin, Y.-M., Hsu, C.-D., Hsieh, H.-Y., Tseng, C.-C. A., & Sun, H. S. (2014) · Journal of Human Genetics · doi:10.1038/jhg.2014.89 · Cited by 16
Metadata
- Authors
- Tremblay, P.-B., Kaiser, R., Sezer, O., Rösler, N., Schelenz, C., Possinger, K., Roots, I., & Brockmöller, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-06-01
- Volume
- 21
- Issue
- 11
- Pages
- 2147-2155
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1998110762
- Cited by
- 157
- References
- 0
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.